These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 16124950)

  • 41. Heparins: their established role in acute coronary syndromes and perspectives in atrial fibrillation.
    Melandri G; Nanni S; Tricoci P; Melloni C; Semprini F; Fallani F; Bracchetti G; Branzi A
    Haematologica; 2001 Nov; 86(11 Suppl 2):54-7. PubMed ID: 11926779
    [No Abstract]   [Full Text] [Related]  

  • 42. Low molecular weight heparin and the treatment of ischemic stroke. Animal results, the reasons for failure in human stroke trials, mechanisms of action, and the possibilities for future use in stroke.
    Jonas S; Quartermain D
    Ann N Y Acad Sci; 2001 Jun; 939():268-70. PubMed ID: 11462779
    [No Abstract]   [Full Text] [Related]  

  • 43. Low-molecular-weight heparins in percutaneous coronary interventions.
    Kar AK; Dutta I
    Indian Heart J; 2003; 55(1):81-7. PubMed ID: 12760596
    [No Abstract]   [Full Text] [Related]  

  • 44. Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes.
    Harding SA; Boon NA; Flapan AD
    Lancet; 2002 Jul; 360(9328):256-7. PubMed ID: 12133681
    [No Abstract]   [Full Text] [Related]  

  • 45. [The value of low-molecular-weight heparins in the treatment of acute coronary syndrome].
    Carlsson J; Tebbe U
    Dtsch Med Wochenschr; 2002 Apr; 127(16):859-65. PubMed ID: 11961704
    [No Abstract]   [Full Text] [Related]  

  • 46. Complications of low-molecular-weight heparin in surgical patients with impaired renal function.
    Hanly EJ; Strobel LM; Mittendorf EA
    Curr Surg; 2005; 62(3):358-61. PubMed ID: 15890228
    [No Abstract]   [Full Text] [Related]  

  • 47. Unfractionated- versus low-molecular-weight-heparin-associated HIT in hospitalized medical patients.
    Fraser GL; Riker RR
    J Hosp Med; 2006 Nov; 1(6):380-1; author reply 381-2. PubMed ID: 17219533
    [No Abstract]   [Full Text] [Related]  

  • 48. On "Current role of antithrombotic agents in the treatment of acute coronary syndromes" (Semin Thromb Hemost 2004;30:627-632).
    Nessel CO
    Semin Thromb Hemost; 2005 Apr; 31(2):248. PubMed ID: 15852228
    [No Abstract]   [Full Text] [Related]  

  • 49. Enoxaparin--a low-molecular-weight heparin.
    Med Lett Drugs Ther; 1993 Aug; 35(903):75-6. PubMed ID: 8393510
    [No Abstract]   [Full Text] [Related]  

  • 50. [Care for life. Central is the patient].
    Hilpert U
    Internist (Berl); 2000 Jan; 41(1):A37. PubMed ID: 10712086
    [No Abstract]   [Full Text] [Related]  

  • 51. A consensus conference on complex biologics and low molecular weight heparins.
    Kalodiki E; Fareed J; Tapson VF; Hoppensteadt DA; Sussman I; Carter CA; Parker S; Harenberg J; Hull R; Rao G; Lovinger DF; Ried LD; Kakkar A; Talarico L; Ofuso F; Bussey HI; Fanikos J; Groce JB; Skinner N; Ahluwalia M; Iqbal O; Jackson CM; Jeske WP; Georges M; Ramacciotti E; Tapson VF; Van Thiel D; Wahi R; Walenga J
    Int Angiol; 2010 Apr; 29(2):193-6. PubMed ID: 20351676
    [No Abstract]   [Full Text] [Related]  

  • 52. Low molecular weight heparins for DVT.
    Ebell MH
    J Fam Pract; 1994 Nov; 39(5):501-2. PubMed ID: 7964550
    [No Abstract]   [Full Text] [Related]  

  • 53. New clinical data shows enoxaparin reduces risk of repeat heart attacks and stroke in patients undergoing PCI.
    Cardiovasc J S Afr; 2006; 17(5):264. PubMed ID: 17117235
    [No Abstract]   [Full Text] [Related]  

  • 54. Management of unstable coronary-artery disease.
    Cohen AT
    Lancet; 2000 Feb; 355(9203):574. PubMed ID: 10683025
    [No Abstract]   [Full Text] [Related]  

  • 55. Low-molecular weight heparin shows considerable benefits in ST-elevation acute myocardial infarction.
    Cardiovasc J S Afr; 2006; 17(2):104. PubMed ID: 16733612
    [No Abstract]   [Full Text] [Related]  

  • 56. [Low molecular weight heparin in acute coronary syndromes].
    Amit G; Weiss AT; Zagher D
    Harefuah; 1999 Sep; 137(5-6):224-8. PubMed ID: 10959327
    [No Abstract]   [Full Text] [Related]  

  • 57. Low-molecular-weight heparin during percutaneous coronary interventions: rationale, results, and recommendations.
    Levine GN; Ferguson JJ
    Catheter Cardiovasc Interv; 2003 Oct; 60(2):185-93. PubMed ID: 14517923
    [No Abstract]   [Full Text] [Related]  

  • 58. [Primary prevention of deep vein thrombosis in non-surgical patients].
    Kröger K
    Dtsch Med Wochenschr; 2005 Jul; 130(28-29):1706-10. PubMed ID: 16003608
    [No Abstract]   [Full Text] [Related]  

  • 59. Is laboratory monitoring of low-molecular-weight heparin therapy necessary? Yes.
    Harenberg J
    J Thromb Haemost; 2004 Apr; 2(4):547-50. PubMed ID: 15102006
    [No Abstract]   [Full Text] [Related]  

  • 60. A survey on the views and attitudes of Italian physicians regarding the prophylaxis and treatment of venous thromboembolism.
    Ageno W; Di Minno G; Agnelli G; Cimminiello C; Imberti D; Polo Friz H; Prandoni P; Scaglione F
    Minerva Med; 2020 Aug; 111(4):370-372. PubMed ID: 31295981
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.